Testing new HIV vaccines for safety and effectiveness
“GLP Toxicology Study for Adjuvanted HIV-1 Immunogen Vaccine Candidates
['FUNDING_OTHER'] · SRI INTERNATIONAL · NIH-11169231
This study is working on new vaccines for HIV to make sure they are safe and can help your body fight the virus, with the goal of offering better options for preventing HIV in the future.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SRI INTERNATIONAL (nih funded) |
| Locations | 1 site (MENLO PARK, UNITED STATES) |
| Trial ID | NIH-11169231 on ClinicalTrials.gov |
What this research studies
This research focuses on the development and testing of new vaccine candidates for HIV. It involves preclinical and translational studies to ensure these vaccines are safe and can generate an immune response. The program will support various stages of vaccine development, including small-scale production and preclinical testing, ultimately leading to clinical trials. Patients may benefit from advancements in HIV prevention through improved vaccine options.
Who could benefit from this research
Good fit: Ideal candidates for participation would be individuals at risk for HIV or those interested in HIV prevention.
Not a fit: Patients who are already living with HIV or those who do not have a risk of exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines for preventing HIV infection.
How similar studies have performed: Previous research in vaccine development for HIV has shown promise, but this approach may offer novel advancements.
Where this research is happening
MENLO PARK, UNITED STATES
- SRI INTERNATIONAL — MENLO PARK, UNITED STATES (ACTIVE)
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.